These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 22713287

  • 1. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes.
    Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A, COMPOSE Investigators and Coordinators.
    Eur J Heart Fail; 2012 Sep; 14(9):1056-66. PubMed ID: 22713287
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers.
    Frey R, Mück W, Unger S, Artmeier-Brandt U, Weimann G, Wensing G.
    J Clin Pharmacol; 2008 Dec; 48(12):1400-10. PubMed ID: 18779378
    [Abstract] [Full Text] [Related]

  • 6. Assessment of the effects of renal impairment on the pharmacokinetics of the soluble guanylate cyclase activator cinaciguat after a single intravenous dose.
    Lettieri JT, Scheerans C, Blunck M, Mazzu AL, Frey R, Mück W, Sundaresan PR.
    J Clin Pharmacol; 2012 Aug; 52(8):1240-7. PubMed ID: 21868716
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Population pharmacokinetics and pharmacodynamics of cinaciguat, a soluble guanylate cyclase activator, in patients with acute decompensated heart failure.
    Mueck W, Frey R.
    Clin Pharmacokinet; 2010 Aug; 49(2):119-29. PubMed ID: 20067336
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of the soluble guanylate cyclase activator cinaciguat in individuals with hepatic impairment.
    Frey R, Scheerans C, Blunck M, Mück W, Gnoth MJ, Unger S, Schmidt A, Wensing G.
    J Clin Pharmacol; 2012 Nov; 52(11):1714-24. PubMed ID: 22162535
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
    Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, Cotter G, Milo O, Laessing U, Zhang Y, Dahlke M, Zymlinski R, Metra M.
    Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Role of soluble guanylate cyclase in renal hemodynamics and autoregulation in the rat.
    Dautzenberg M, Kahnert A, Stasch JP, Just A.
    Am J Physiol Renal Physiol; 2014 Nov 01; 307(9):F1003-12. PubMed ID: 25209860
    [Abstract] [Full Text] [Related]

  • 15. Haemodynamic and clinical effects of ularitide in decompensated heart failure.
    Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Lüss H, Meyer M.
    Eur Heart J; 2006 Dec 01; 27(23):2823-32. PubMed ID: 17074775
    [Abstract] [Full Text] [Related]

  • 16. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
    Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G.
    Lancet; 2009 Apr 25; 373(9673):1429-39. PubMed ID: 19329178
    [Abstract] [Full Text] [Related]

  • 17. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
    Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC.
    Hypertension; 2007 May 25; 49(5):1128-33. PubMed ID: 17325237
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.
    Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, Wagoner LE, Givertz MM, Liang CS, Neibaur M, Haught WH, LeJemtel TH.
    N Engl J Med; 2000 Jul 27; 343(4):246-53. PubMed ID: 10911006
    [Abstract] [Full Text] [Related]

  • 20. [Acute hemodynamic effects of intravenous recombinant human brain natriuretic peptide in patients with acute myocardial infarction complicated with heart failure].
    Li SQ, Fu XH, Liu J, Gu XS, Zhang J, Fan XN, Jiang YF, Miao Q.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Jan 27; 34(1):23-7. PubMed ID: 16626544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.